Airway Therapeutics erhält eine Förderung des NIH in Höhe von 1,9 Millionen US-Dollar zur Weiterführung der Phase-2b/3-Studie mit Zelpultide alfa zur Prävention der bronchopulmonalen Dysplasie

Phase 2Zelpultide alfaPositive

AI Analysis

Summary

Airway Therapeutics received a $1.9 million NIH grant to advance the Phase 2b/3 study of Zelpultide alfa for prevention of bronchopulmonary dysplasia, supported by positive safety and tolerability data from Phase 1b trials.

Clinical Trial Data

Phase

Phase 2b/3

Outcome Details

NIH grant of $1.9 million awarded to continue Phase 2b/3 study; positive safety and tolerability results from Phase 1b study

Importance:5/10

Sentiment:

0.70

NIH fundingclinical developmentnon-dilutive capitalbronchopulmonary dysplasiaPhase 1b data

Read the original article

Published by PR Newswire Biotech on September 29, 2026 8:23 PM

Read Original